Table 4 Global description of the intervention doses in the 24 high schools participating in the PRALIMAP trial
N | mean | standard deviation | median | Q1 | Q3 | min | max | |||
|---|---|---|---|---|---|---|---|---|---|---|
Education | NPDA* | year 1 | 24 | 9.0 | 3.5 | 8.3 | 6.6 | 12.5 | 3.4 | 13.9 |
year 2 | 24 | 7.7 | 2.8 | 7.8 | 5.5 | 10.0 | 2.5 | 13.2 | ||
PDA** | year 1 | 12 | 8.2 | 1.9 | 7.8 | 7.3 | 9.3 | 4.7 | 11.8 | |
year 2 | 12 | 6.3 | 3.5 | 7.5 | 2.7 | 8.5 | 0.5 | 10.9 | ||
Screening | NPDA | year 1 | 24 | 5.2 | 3.7 | 5.0 | 2.3 | 8.4 | 0.0 | 11.9 |
year 2 | 24 | 5.0 | 3.4 | 5.4 | 1.8 | 7.9 | 0.0 | 10.1 | ||
PDA | year 1 | 12 | 6.3 | 3.5 | 6.6 | 3.1 | 9.3 | 1.2 | 10.8 | |
year 2 | 12 | 3.6 | 2.7 | 3.0 | 1.9 | 4.8 | 0.5 | 8.8 | ||
Environment | NPDA | year 1 | 24 | 6.4 | 2.3 | 7.0 | 5.8 | 7.8 | 1.8 | 9.4 |
year 2 | 24 | 5.7 | 2.0 | 6.1 | 4.6 | 7.3 | 1.2 | 9.6 | ||
PDA | year 1 | 12 | 7.8 | 1.8 | 7.6 | 6.8 | 8.4 | 5.2 | 12.5 | |
year 2 | 12 | 8.2 | 3.1 | 8.6 | 6.9 | 9.7 | 0.3 | 12.1 |